Synmosa Group

Company Profile
Synmosa Group

The Synmosa Group

Synmosa Biopharma Corporation was established in 1980. From its start-up phase as a foreign product agent, after numerous business acquisitions, it has been formed as a complete enterprise organization that strives to work towards multifaceted developments, including agencies, manufacturing, sub-manufacturing, and research and developments. Its business entities in Taiwan comprise hospitals, clinics, pharmacies, and robust marketing channel teams. Overseas strategy partners are located in Mainland China, and more than 10 countries in Southeast Asia, Europe, America, Australia, and Japan. 

Since acquiring German Boehringer Ingelheim’s Taiwanese plant in 2005, Synmosa has managed to successfully transform into an international pharmaceutical company with the inheritance of the persistence in quality control and facility along with the specifications of International standards. In addition to hardware advancements, Synmosa acts as an OEM/ODM agent for Boehringer Ingelheim because of its recognized capability in their manufacturing process and software. Meanwhile, it has managed to acquire the Eli Lilly pharmaceutical’s plant in Taiwan in 2008. Constant acquisitions in combination with Synmosa’s strategy in talent nurturing and retaining enables Synmosa to successfully transform itself into a global company with international standards and with excellent quality and productivity assurance.

Following the core beliefs of integrity, credibility, responsibility, and innovation, the Synmosa Group has experienced rapid growth in the past 30 years. With research team of experts, a well-developed business structure, professional production processes and firm business basis, Synmosa has focused on pharmaceutical development and technology platform on the fields of research for respiratory, sex hormones, cardiovascular, urology, and oncology. With our attempts to constantly invest in the research of new patent drugs and novel therapeutic methods for health of human beings, Synmosa will continue to contributing to the society and become a model company among the very best.

more >

Year of Establishment: 1980

Total Assets(USD): 50,000,000 To 54,999,999

Total Number of Staff: more than 500

Main Competitive Advantages:

Other Competitive Advantages: *Synmosa specializes in four major technology manufacture platform including MDI, sex hormone, nasal spray, and effervescent which enable it to develop HFA MDI, effervescent, control release formulations, and products of wide-range therapeutic areas which include respiratory, cardiovascular, Hormone therapy, urology, muscles relaxant, and food supplements. *Owning automatic production facilities which are designed to cater to international standard formulations including tablets, meter dose inhalers, liquid, granule, capsule, and production. *Sex hormones are produced in an independently specialized factory, its high quality has won itself a remarkable reputation as it hold the first place in Taiwan market share ranking. *Well-developed and internationally competitive MDI technology platform, its respiratory products are the second place in Taiwan market share. *Synmosa's plant and laboratory equip the high standard inspection facility for nasal aerosol formulations which ensure the product quality. *With consistent and strict process of R&D, manufacturing, and quality control, Synmosa’s products have been acknowledged with national quality award and the accreditation, and earned a good reputation to build a strong network in medical market.

Patents and Copyrights: 1. Counter for metered dose inhaler: US 8215299, CN102218180B 2. Compound composition for inhalation used for treating asthma: US 8877740, AU2011307899, NZ 607900, KR 10-1475262, HK1169334, CN 102416179 3. Method For Preparing Metered Dose Sprayed Inhaler For Treating Respiratory Disease: TW I399202, SG 2014011597 4. The Composition And Method Of Preparing Acemetacin Retard Pellet And Its Dosage Form: TW I257312 5. Cuyantong slow-releasing round-particle composition and preparation method : CN1579369 6. Composition Of Increasing Dissolution Rate For Lacidipine Tablet And Preparation Method Thereof: TW I265813

Certificates/Standards View More
Send your message to this supplier
  • From:
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service